Medical Device News Magazine

Morton Plant Hospital First in Tampa Bay to Use New Treatment for Restenosis

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Morton Plant Hospital recently became the first hospital in the Tampa Bay area to use a drug-coated balloon to treat in-stent restenosis. The hospital was ranked #1 in Florida for Cardiac Surgery in 2023 by Healthgrades, where the area’s first robotic-assisted coronary artery bypass surgery took place in early June.

BayCare Medical Group’s Interventional Cardiologist Lang Lin, MD, and her expert team of medical professionals at Morton Plant Hospital performed the first procedure with the drug-coated balloon earlier this month.

Restenosis occurs when an artery that has previously been stented narrows again because of plaque or scar tissue.

Treating in-stent restenosis remains a significant challenge for both patients and cardiologists, even 20 years after drug-eluting stents (which are coated with medicine to keep arteries open) became the standard of care.” Dr. Lin said.

Until now, in-stent restenosis has most commonly been treated in one of two ways: by placing an additional stent in the stent of the artery that has narrowed again or by performing coronary artery bypass surgery. The challenge with two or more layers of stents is that additional stents become less effective and more difficult to treat. Coronary artery bypass surgery has increased risks with older patients and sometimes limited bypass target vessels.

The new drug-coated balloon, AGENT™ from Boston Scientific, was approved by the U.S. Food and Drug Administration (FDA) for commercial use in March. The balloon catheter, the first drug-coated coronary balloon in the United States, reopens the narrowed stent and releases the high concentration of drugs to prevent scar tissue from forming and blocking the artery wall again.

“We are pleased to have the opportunity to offer this cutting-edge treatment to our patients,” Dr. Lin said. “The new technology will help us to treat certain patients with in-stent restenosis without the need for another stent, invasive surgery or brachytherapy (radiation).”

For more information on heart and vascular services at BayCare: BayCare’s Heart and Vascular Services.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”